renal-cell carcinoma (advanced)

     

Select
Display
Trial Studied trt Control trt patientstagsNCTROB Result

All mechanism

not classified
Disruptor-1BNC105P + everolimuseverolimus -
Motzer, 2015 ongoing lenvatinibeverolimusNCT01136733 ongoing
apitolisib
Powles, 2014apitolisibeverolimus -
axitinib
AXIS (Rini), 2011axitinibsorafenibNCT00678392suggesting
Qin, 2012axitinibsorafenib -
bevacizumab
CALGB 90206, 2010bevacizumab plus interferon alfainterferon alphasuggesting
AVOREN, 2007bevacizumab plus interferon alfainterferon alphasuggesting
Yang, 2003bevacizumabplaceboExploratory -
cabozantinib
METEOR, 2015cabozantinibeverolimus after VEGFR-targeted therapy failure 2nd line NCT01865747Risk of bias suggesting
CABOSUN, 2017cabozantinibsunitinibfirst-line therapy in patients with intermediate- or poor-risk 1st line NCT01835158Exploratory suggesting
dovitinib
GOLDdovitinibsorafenibNCT01223027negative
everolimus
RECORD-1, 2008everolimusplaceboNCT00410124suggesting
RECORD 3, 2014everolimussunitinibNCT00903175 -
nivolumab
CheckMate 025, 2015nivolumabeverolimusNCT01668784suggesting
pazopanib
VEG105192, 2010pazopanibplaceboNCT00334282suggesting
Sternberg, 2010pazopanibplacebosuggesting
COMPARZ, 2013pazopanibsunitinibNCT00720941negative
sorafenib
Escudier, 2009sorafenibinterferon alphaExploratory negative
TARGET, 2007sorafenibplaceboNCT00073307Low risk of bias suggesting
Ratain, 2006sorafenibplaceboExploratory -
sunitinib
Motzer, 2007sunitinibinterferon alphaNCT00083889suggesting
SWITCHsunitinibsorafenibNCT00732914 -
temsirolimus
ARCC (Hudes) temsirolimus alone, 2007temsirolimusinterferon alphaNCT00065468suggesting
INTORSECT, 2014temsirolimussorafenibNCT00474786negative
tivozanib
TIVO-1, 2013tivozanibsorafenibNCT01030783suggesting

angiogenesis inhibitors

bevacizumab
CALGB 90206, 2010bevacizumab plus interferon alfainterferon alphasuggesting
AVOREN, 2007bevacizumab plus interferon alfainterferon alphasuggesting
Yang, 2003bevacizumabplaceboExploratory -

immune checkpoint inhibition

atezolizumab
NCT02420821 ongoing atezolizumab + bevacizumab1LNCT02420821Risk of bias ongoing
avelumab
JAVELIN Renal 101 ongoing avelumab + axitinibsunitinib1L, PDL1 positiveNCT02684006Risk of bias ongoing
nivolumab
Chekmate 025 (Motzer), 2015nivolumabeverolimus2LNCT01668784Risk of bias suggesting
CheckMate-214, 2017nivolumab + ipilimumabsunitinib1LNCT02231749Risk of bias suggesting
pembrolizumab
KEYNOTE-426 ongoing pembrolizumab + axitinibsunitinibNCT02853331 ongoing

Immunotherapy

nivolumab
CheckMate 025, 2015nivolumabeverolimusNCT01668784suggesting
CheckMate 214 ongoing nivolumab+ ipilimumabsunitinibNCT02231749 ongoing

mTOR inhibitor

everolimus
RECORD-1, 2008everolimusplaceboNCT00410124suggesting
RECORD 3, 2014everolimussunitinibNCT00903175 -
temsirolimus
ARCC (Hudes) temsirolimus alone, 2007temsirolimusinterferon alphaNCT00065468suggesting
INTORSECT, 2014temsirolimussorafenibNCT00474786negative

multi target TKI

not classified
Disruptor-1BNC105P + everolimuseverolimus -
Motzer, 2015 ongoing lenvatinibeverolimusNCT01136733 ongoing
apitolisib
Powles, 2014apitolisibeverolimus -
axitinib
AXIS (Rini), 2011axitinibsorafenibNCT00678392suggesting
Qin, 2012axitinibsorafenib -
cabozantinib
METEOR, 2015cabozantinibeverolimus after VEGFR-targeted therapy failure 2nd line NCT01865747Risk of bias suggesting
CABOSUN, 2017cabozantinibsunitinibfirst-line therapy in patients with intermediate- or poor-risk 1st line NCT01835158Exploratory suggesting
dovitinib
GOLDdovitinibsorafenibNCT01223027negative
pazopanib
Sternberg, 2010pazopanibplacebosuggesting
VEG105192, 2010pazopanibplaceboNCT00334282suggesting
COMPARZ, 2013pazopanibsunitinibNCT00720941negative
sorafenib
Escudier, 2009sorafenibinterferon alphaExploratory negative
TARGET, 2007sorafenibplaceboNCT00073307Low risk of bias suggesting
Ratain, 2006sorafenibplaceboExploratory -
sunitinib
Motzer, 2007sunitinibinterferon alphaNCT00083889suggesting
SWITCHsunitinibsorafenibNCT00732914 -
tivozanib
TIVO-1, 2013tivozanibsorafenibNCT01030783suggesting